Emerson Electric Co.

EMR Industrials · Specialty Industrial Machinery
Delayed 15 min
Last close
$162.15
Oct 16, 2026
52-week range
$122.64 — $166.35
-3% from high
Market cap
90.4B
Diluted basis
Dividend yield
1.4%
P/E
35.5
Trailing
Verdict status · Oct 16, 2026

Not yet scored

Filing.fyi has not computed forensic scores for EMR yet. Scores appear after the company's next data refresh.

No verdict yet
RED DEEP Scores pending shown after the next data refresh
Composite Health
AI synthesis · written from this company's SEC filings · not investment advice

What the filing actually says.

AI · forensic preset

The filing supports a narrower reading than the headline earnings growth suggests. Management's own adjusted EPS bridge shows operations adding $0.08 and foreign currency adding $0.07, while software renewal timing subtracted $0.09. The 27 percent rise in earnings attributable to common stockholders, to $618 million, is largely a comparison effect. The prior-year quarter carried $168 million of acquisition and divestiture fees and related costs, mainly tied to AspenTech, and the filing describes a $143 million decrease in those fees as a major driver of lower other deductions. Segment results show the mix shifting. Test & Measurement grew underlying sales 12 percent, offsetting weakness in Control Systems & Software, where sales were $1,089 million and underlying sales fell 2 percent. Intelligent Devices adjusted EBITA margin rose to 27.9 percent, yet Final Control restructuring costs rose to $25 million from $3 million, a change readers may want to look at more closely. Geographically, underlying sales were up 9 percent in the U.S. but down 5 percent internationally, with China down 9 percent. Management attributes about 1 percentage point of underlying sales to the Middle East conflict and warns that continuation or escalation could adversely affect future periods. Readers may also want to follow the IEEPA refund disclosures, since the CBP claims portal launched April 20, 2026 could eventually produce a benefit the company has not recorded. Against the longer series, fiscal 2025 revenue of $18.02 billion sits well below the $19.63 billion reported for fiscal 2022. Overall, the filing shows steady reported growth with thinner underlying momentum and a higher interest burden.

Catalyst.For the quarter ended March 31, 2026, net sales rose 3 percent to $4,562 million from $4,432 million, but foreign currency translation added 2.5 percent, so underlying sales rose only 0.5 percent. That underlying figure reflected 3.5 percent higher price offset by 3 percent lower volume. Test & Measurement was the clear driver, with sales of $414 million, up 16 percent reported and 12 percent underlying on strength in aerospace and defense and semiconductors. Diluted EPS rose to $1.10 from $0.86, though the prior-year quarter carried AspenTech acquisition costs, and adjusted diluted EPS grew 4 percent to $1.54. For fiscal 2025, revenues were $18.02 billion, up from $17.49 billion in fiscal 2024.

Hidden risk.Reported earnings growth flatters the operating picture. Interest expense, net more than doubled to $84 million from $41 million in the quarter. The effective tax rate fell to 22 percent from 32 percent, largely because the prior year included AspenTech-related discrete tax items, so the comparison base is distorted. Software and Systems adjusted EBITA margin fell 2.5 points to 29.2 percent, with management attributing about 3 points to software renewal timing. Tariffs reduced gross margin by roughly 0.8 points, and the company recorded no benefit for possible IEEPA tariff refunds because their amount and timing remain uncertain.

Market signals · from trading data, not filings

What traders are betting.

The scores above come from what EMR reports to the SEC. These readings come from how traders are positioned in its shares. They change quickly, they can be wrong, and they are not part of the verdict.
Short interest Shares sold short · reported twice a month
1.6%
of the shares available to trade
Low
0%5% · 10% · 20%25%+

The metric

Shares that traders have borrowed and sold, betting the price will fall, and not yet bought back. Brokers report the total to FINRA twice a month. Days to cover divides it by the shares that change hands on a typical day.

Shares sold short
8.8M
Change since Aug 31
+0.3%
Days to cover
3.7

What it tells us

Few traders are betting against EMR. Levels this low are common for large, widely held companies.

Little changed since the Aug 31 report (+0.3%).

At normal trading volume, short sellers would need about 3.7 days to buy back every borrowed share.

How investors use it

  • Squeeze watching. Some aggressive traders seek out heavily shorted stocks, betting that good news will force short sellers to buy back shares and push the price higher.
  • Hedging. Funds short one company to offset risk in another, often owning a stronger business and shorting a weaker one in the same industry.
  • Timing. Chart-based traders pair rising short interest with price patterns, such as a break below a level where buyers used to step in, to decide when to enter or exit.
  • Warning sign. Some owners treat a sharp rise in short interest as a red flag and respond by tightening stop-loss orders or holding smaller positions.

Lesson: short interest, explained →

Short-interest report for Sep 30, 2026, via Yahoo Finance. Reports come out about a week and a half after that date.

SEC filings · last 12 months

Annual report, quarterly reports & proxy statement

The annual report (10-K), quarterly reports (10-Q), proxy statement (DEF 14A) and current reports (8-K) Emerson Electric filed in the last 12 months, each linked to the original document on SEC EDGAR.

  • Oct 13, 2026
    8-K
    Current reportItem 2.02: Results of operations (earnings)0
    EDGAR →
  • Aug 4, 2026
    10-Q
    Quarterly report0
    EDGAR →
  • May 5, 2026
    10-Q
    Quarterly report (2026-03-31)Period: 2026-03-310
    EDGAR →
  • May 5, 2026
    8-K
    Current report (2026-05-05)Item 2.02: Results of operations (earnings); Item 5.02: Departure/appointment of officers or directors; Item 7.01: Regulation FD disclosure (investor materials)0
    EDGAR →
  • Feb 13, 2026
    8-K
    Current report (2026-02-10)Item 1.01: Signed a material agreement0
    EDGAR →
  • Feb 6, 2026
    8-K
    Current report (2026-02-03)No specific items found in 8-K.0
    EDGAR →
  • Dec 12, 2025
    DEF 14A
    Proxy statement (2025-09-30)0
    EDGAR →
  • Nov 10, 2025
    10-K
    Annual report (2025-09-30)Period: 2025-09-300
    EDGAR →
Further reading · curated for this filing

If this case caught your eye

Affiliate links — Filing.fyi earns a commission on Amazon purchases. We pick the books first, attach the link second.

Financial Shenanigans

Howard M. Schilit

Schilit's framework for the seven shenanigan types is the standard reference for the kind of MD&A pattern-matching this site does.

View on Amazon →

The Interpretation of Financial Statements

Benjamin Graham

The original — and still the clearest — explanation of why working-capital trends matter more than headline earnings.

View on Amazon →

Quality of Earnings

Thornton L. O'glove

Out of print, expensive, worth it. The chapter on receivables-vs-revenue divergence applies almost word-for-word to most distressed filings.

View on Amazon →